H1B Report
Side-by-side comparison

AstraZeneca Pharmaceuticals LP vs INFOSYS LIMITED

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
AstraZeneca Pharmaceuticals LP
DERank #FEIN 23-2967016
Entity B
INFOSYS LIMITED
TXRank #1FEIN 58-1760235

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricAstraZeneca Pharmaceuticals LPINFOSYS LIMITED
Total filings750205,263
Certified %94.27%99.55%
Denied %1.60%0.21%
Withdrawn %1.60%0.20%
Cert-withdrawn %2.53%0.05%
Rank#1
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateDETX

Outcomes — AstraZeneca Pharmaceuticals LP

DOL case-status mix.

Outcome breakdown: Certified 94.3%, Cert-withdrawn 2.5%, Withdrawn 1.6%, Denied 1.6%
Outcome breakdown
OutcomeShare
Certified94.3%
Cert-withdrawn2.5%
Withdrawn1.6%
Denied1.6%
Certified94.3%
Cert-withdrawn2.5%
Withdrawn1.6%
Denied1.6%

Outcomes — INFOSYS LIMITED

DOL case-status mix.

Outcome breakdown: Certified 99.5%, Cert-withdrawn 0.0%, Withdrawn 0.2%, Denied 0.2%
Outcome breakdown
OutcomeShare
Certified99.5%
Cert-withdrawn0.0%
Withdrawn0.2%
Denied0.2%
Certified99.5%
Cert-withdrawn0.0%
Withdrawn0.2%
Denied0.2%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

AstraZeneca Pharmaceuticals LP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201010
FY201113
FY20126
FY20136
FY201412
FY201527
FY201622
FY201726
FY201865
FY201944
FY202054
FY202185
FY202229
FY202339
FY2024107
FY2025136
FY202669
INFOSYS LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,164
FY20111,681
FY201214,701
FY201332,232
FY201423,749
FY201533,214
FY201625,335
FY201720,571
FY201811,569
FY201921,420
FY202016
FY202129
FY202222
FY20232,269
FY20245,943
FY20255,790
FY20264,558

Top 5 occupations — AstraZeneca Pharmaceuticals LP

Top 5 occupations — INFOSYS LIMITED

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.